Celexion (Key Antibody Assets) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Latest Deal Amount
  • $4M
Latest Deal Amount

Celexion (Key Antibody Assets) General Information

Description

Yeast display platform. Platform for generating monoclonal antibodies and other antibody-related assets, which enables highly efficient interrogation of drug targets such as checkpoint proteins.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Buildings and Property
Other Industries
Other Healthcare Technology Systems
Biotechnology
Acquirer
Primary Office
  • One Kendall Square
  • Suite B6103
  • Cambridge, MA 02139
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Celexion (Key Antibody Assets) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Corporate Asset Purchase 08-Apr-2015 $4M 000 Completed
To view Celexion (Key Antibody Assets)’s complete valuation and funding history, request access »

Celexion (Key Antibody Assets) Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Celexion Corporation Majority 000 0000 000000 0
To view Celexion (Key Antibody Assets)’s complete investors history, request access »